These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35218560)
1. Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities. Lupia M; Melocchi V; Bizzaro F; Lo Riso P; Dama E; Baronio M; Ranghiero A; Barberis M; Bernard L; Bertalot G; Giavazzi R; Testa G; Bianchi F; Cavallaro U Int J Cancer; 2022 Jul; 151(2):240-254. PubMed ID: 35218560 [TBL] [Abstract][Full Text] [Related]
2. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872 [TBL] [Abstract][Full Text] [Related]
3. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer. Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492 [TBL] [Abstract][Full Text] [Related]
4. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036 [TBL] [Abstract][Full Text] [Related]
5. A single-cell landscape of high-grade serous ovarian cancer. Izar B; Tirosh I; Stover EH; Wakiro I; Cuoco MS; Alter I; Rodman C; Leeson R; Su MJ; Shah P; Iwanicki M; Walker SR; Kanodia A; Melms JC; Mei S; Lin JR; Porter CBM; Slyper M; Waldman J; Jerby-Arnon L; Ashenberg O; Brinker TJ; Mills C; Rogava M; Vigneau S; Sorger PK; Garraway LA; Konstantinopoulos PA; Liu JF; Matulonis U; Johnson BE; Rozenblatt-Rosen O; Rotem A; Regev A Nat Med; 2020 Aug; 26(8):1271-1279. PubMed ID: 32572264 [TBL] [Abstract][Full Text] [Related]
6. TRAF4 promotes the malignant progression of high-grade serous ovarian cancer by activating YAP pathway. Luo X; Cao J; Zhang C; Huang H; Liu J Biochem Biophys Res Commun; 2022 Oct; 627():68-75. PubMed ID: 36029535 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray. Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656 [TBL] [Abstract][Full Text] [Related]
8. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples. Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608 [TBL] [Abstract][Full Text] [Related]
9. Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis. Chen LY; Huang RL; Su PH; Chu LH; Weng YC; Wang HC; Lai HC; Wen KC Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563509 [TBL] [Abstract][Full Text] [Related]
10. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers. Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089 [TBL] [Abstract][Full Text] [Related]
11. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564 [TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993 [TBL] [Abstract][Full Text] [Related]
13. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids. Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549 [TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 ( Yildirim N; Kocal GC; Isik Z; Saatli B; Saygili U; Uysal T; Ulukus C; Koyuncuoglu M; Ellidokuz H; Basbinar Y Reprod Sci; 2019 Jun; 26(6):794-805. PubMed ID: 30198418 [TBL] [Abstract][Full Text] [Related]
15. Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread. Bachmayr-Heyda A; Auer K; Sukhbaatar N; Aust S; Deycmar S; Reiner AT; Polterauer S; Dekan S; Pils D Oncotarget; 2016 Jun; 7(26):39640-39653. PubMed ID: 27172797 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53. Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283 [TBL] [Abstract][Full Text] [Related]
17. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261 [TBL] [Abstract][Full Text] [Related]
18. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis. Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542 [TBL] [Abstract][Full Text] [Related]
19. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer. Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151 [TBL] [Abstract][Full Text] [Related]
20. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]